Table 3.
Use of lipid lowering therapies before and after the visit at specialized cardiovascular clinic.
| Healthy participants and other risk factor |
||||||
|---|---|---|---|---|---|---|
| ASCVD |
DM |
MOD-LOW RISK |
HIGH RISK |
VERY HIGH RISK |
Overall |
|
| (N = 1432) | (N = 982) | (N = 221) | (N = 1667) | (N = 1141) | (N = 5443) | |
| Treatment before visit at specialized cardiovascular clinic | ||||||
| No LLT | 428 (29.9%) | 622 (63.3%) | 192 (86.9%) | 1319 (79.1%) | 870 (76.2%) | 3431 (63.0%) |
| Other LLTa | 36 (2.5%) | 58 (5.9%) | 3 (1.4%) | 67 (4.0%) | 45 (3.9%) | 209 (3.8%) |
| Low intensity statinb | 61 (4.3%) | 49 (5.0%) | 1 (0.5%) | 38 (2.3%) | 31 (2.7%) | 180 (3.3%) |
| Moderate intensity statinb | 394 (27.5%) | 184 (18.7%) | 23 (10.4%) | 183 (11.0%) | 150 (13.1%) | 934 (17.2%) |
| High intensity statinb | 501 (35.0%) | 69 (7.0%) | 2 (0.9%) | 60 (3.6%) | 45 (3.9%) | 677 (12.4%) |
| iPCSK9c |
12 (0.8%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
12 (0.2%) |
| Treatment after visit at specialized cardiovascular clinic | ||||||
| No LLT | 216 (15.1%) | 300 (30.5%) | 113 (51.1%) | 677 (40.6%) | 429 (37.6%) | 1735 (31.9%) |
| Other LLTa | 19 (1.3%) | 50 (5.1%) | 11 (5.0%) | 84 (5.0%) | 28 (2.5%) | 192 (3.5%) |
| Low intensity statinb | 21 (1.5%) | 13 (1.3%) | 1 (0.5%) | 25 (1.5%) | 13 (1.1%) | 73 (1.3%) |
| Moderate intensity statinb | 439 (30.7%) | 344 (35.0%) | 65 (29.4%) | 552 (33.1%) | 398 (34.9%) | 1798 (33.0%) |
| High intensity statinb | 718 (50.1%) | 273 (27.8%) | 31 (14.0%) | 324 (19.4%) | 272 (23.8%) | 1618 (29.7%) |
| iPCSK9c | 18 (1.3%) | 1 (0.1%) | 0 (0%) | 5 (0.3%) | 1 (0.1%) | 25 (0.5%) |
Data is shown as mean and standard deviation for continuous variables and frequencies and percentages for categorical variables.
Two patients missing due to incomplete recording of treatment administrated at the visit.
a
Fibrates, niacin, Omega-3 fatty acids.
b
Monotherapy or in combination with Ezetimibe.
c
Monotherapy or in combination with other LLT.